Who is the CEO of Biobijou?

According to the DART company overview, Biobijou's representative director is 양준호 (name as registered in Korean). The company was founded on 2018-07-12.

Where is Biobijou listed?

Biobijou trades on the Korea Exchange KOSDAQ market under the ticker 489460. Its fiscal year ends in December.

Does Biobijou pay a dividend?

Yes. For fiscal 2025, Biobijou paid a cash dividend of ₩100 per common share, a 0.7% yield as stated in its annual report, with a payout ratio of 36.0%.

Does Biobijou have any recent filing signals?

Signals detected automatically from DART filings and quarterly results: Dilution risk (rights offering or CB/BW/EB issue decided in the past 90 days); Profit +50% (latest quarterly operating profit up more than 50% year on year); Op. margin 20%+ (operating margin of 20% or more on quarterly revenue of at least ₩5bn). These are factual flags, not investment advice.

Which companies are in the same industry as Biobijou?

Under the Korean Standard Industrial Classification recorded on DART, Biobijou is grouped with 100 other listed companies in specialty chemicals. The most covered in Korean news over the past 30 days are Apr, Cosmax and KCC.

Biobijou KRX:489460KOSDAQ

바이오비쥬 · Korean news coverage and regulatory filings, organized.

한국어

Articles, 24h0

Articles, 7 days0

DART filings, 7 days0

Articles tracked10since Sep 11

In Q2 2026, Biobijou reported revenue of ₩9.9bn, up 58.3% year on year, and operating profit of ₩2.7bn. Biobijou (바이오비쥬) appeared in 0 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 19 with 2 articles.

Filing signals Profit +50% Op. margin 20%+ Dilution risk Screener

Biobijou quarterly results consolidated, KRW

Quarter	Revenue	YoY	Operating profit	Net income
Q2 2026	₩9.9bn	+58.3%	₩2.7bn margin 27.4%	₩2.5bn
Q1 2026	₩8.0bn	-30.8%	₩2.6bn margin 32.4%	₩2.9bn
Q4 2025 derived	₩4.0bn	-56.4%	−₩2.7bn margin −68.0%	−₩1.4bn
Q3 2025	₩6.6bn	-4.2%	₩2.4bn margin 36.9%	₩2.4bn
Q2 2025	₩6.2bn	-11.6%	₩1.6bn margin 26.1%	₩575m
Q1 2025	₩11.6bn	–	₩2.1bn margin 18.0%	₩1.7bn
Q4 2024 derived	₩9.2bn	–	₩3.2bn margin 34.3%	₩3.4bn
Q3 2024	₩6.9bn	–	₩2.3bn margin 33.3%	₩1.4bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Biobijou top stories 2 weeks, by number of outlets

1
양준호 바이오비쥬 대표 “셀리비온 내년 상반기 日 진출…현지 업체와 최종조건 조율 중”
1 outlets · 2 articlesFirst report Oct 19 08:01 이데일리

Latest Biobijou news Korean headlines

Oct 1908:03
양준호 바이오비쥬 대표 “셀리비온 내년 상반기 日 진출…현지 업체와 최종조건 조율 중”
이데일리
1 more on this story · 1 outlets
- 양준호 바이오비쥬 대표 “셀리비온 내년 상반기 日 진출…현지 업체와 최종조건 조율 중”이데일리 · Oct 19 08:01
Oct 1315:29

바이오비쥬, 1만 3000원 고지 다시 밟나...중장기 성장 동력 가동에 회복세 뚜렷
이데일리
Oct 708:03
美서 대박친 바이오비쥬, 올해 사상 최대 실적 기대...내년 더 좋다
이데일리Earnings
1 more on this story · 1 outlets
- 美서 대박친 바이오비쥬, 올해 사상 최대 실적 기대...내년 더 좋다이데일리 · Oct 7 08:02
Sep 1113:22

바이오비쥬, '셀리비온' 새 성장축으로...외형 성장 속도 낸다
톱데일리
Sep 1113:21

바이오비쥬, 600억 규모 투자유치에 9%대 강세
뉴시스경제
Sep 1110:45

코스나인·바이오비쥬 주가 화색도네…화장품주 다시 불붙나
핀포인트뉴스Cosnine
Sep 1109:40

“단순 볼륨 채우기 끝났다”…바이오비쥬, 동종진피 ECM ‘셀리비온 린제이’ 앞세워 스킨 리바이저 시장 정조준
이투데이
Sep 1109:29

[더벨]바이오비쥬 "셀리비온 앞세워 글로벌 톱티어 도약"
머니투데이

Articles per day 2 weeks

219

Company profile

CEO: 양준호
Industry: Specialty chemicals
Founded: 2018-07-12
Fiscal year-end: December
Head office: 경기도 하남시
Website: biobijou.co.kr
Quotes & chart: Naver Securities (Korean)

From the DART company overview.

Biobijou dividends annual report

Korea dividend rankings

Year	Per share	Yield	Payout
FY2025	₩100	0.7%	36.0%
FY2024	–	–	–
FY2023	–	–	–

Major shareholders latest 5%+ report per holder

Korea 5% stake disclosures

청담글로벌50.85%
마이센보유한공사6.22%

Each holder's most recent 5% ownership report on DART; names as filed in Korean.

Same industry Specialty chemicals

All in industry

Company	Latest quarter op. profit	Articles 30d
Apr	₩191bn	339
Cosmax	₩73.7bn	264
KCC	₩129bn	253
Amorepacific	₩117bn	221
Hanwha	₩2.41tn	189
Kolmar Korea	₩110bn	166
LG H&H	₩103bn	165
SKC	−₩14.4bn	85

Compare Biobijou side by side with these companies

Biobijou DART filings

Oct 216:00

5% ownership report 주식등의대량보유상황보고서(약식)
Ownership reports
Sep 1816:27

Other 증권발행결과(자율공시) (제1회차 CB)
Other
Sep 1015:38

Convertible bond 주요사항보고서(전환사채권발행결정)
Capital & M&A

Mentioned alongside 2 weeks

No co-mentioned companies yet.

Biobijou FAQ

Who is the CEO of Biobijou?: According to the DART company overview, Biobijou's representative director is 양준호 (name as registered in Korean). The company was founded on 2018-07-12.
Where is Biobijou listed?: Biobijou trades on the Korea Exchange KOSDAQ market under the ticker 489460. Its fiscal year ends in December.
What were Biobijou's latest quarterly results?: In Q2 2026, Biobijou reported revenue of ₩9.9bn, up 58.3% year on year, and operating profit of ₩2.7bn. Figures come from reports filed on DART.
Does Biobijou pay a dividend?: Yes. For fiscal 2025, Biobijou paid a cash dividend of ₩100 per common share, a 0.7% yield as stated in its annual report, with a payout ratio of 36.0%.
Does Biobijou have any recent filing signals?: Signals detected automatically from DART filings and quarterly results: Dilution risk (rights offering or CB/BW/EB issue decided in the past 90 days); Profit +50% (latest quarterly operating profit up more than 50% year on year); Op. margin 20%+ (operating margin of 20% or more on quarterly revenue of at least ₩5bn). These are factual flags, not investment advice.
Which companies are in the same industry as Biobijou?: Under the Korean Standard Industrial Classification recorded on DART, Biobijou is grouped with 100 other listed companies in specialty chemicals. The most covered in Korean news over the past 30 days are Apr, Cosmax and KCC.